These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33824928)

  • 21. [Nephrologists and porphyrias].
    Canavese C; Gabrielli D; Guida C; Cappellini MD
    G Ital Nefrol; 2002; 19(4):393-412. PubMed ID: 12369042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute hepatic porphyrias: Recommendations for evaluation and long-term management.
    Balwani M; Wang B; Anderson KE; Bloomer JR; Bissell DM; Bonkovsky HL; Phillips JD; Desnick RJ;
    Hepatology; 2017 Oct; 66(4):1314-1322. PubMed ID: 28605040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute Porphyrias.
    Besur S; Schmeltzer P; Bonkovsky HL
    J Emerg Med; 2015 Sep; 49(3):305-12. PubMed ID: 26159905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Acute hepatic porphyria and its neurological syndrome].
    Bont A; Steck AJ; Meyer UA
    Schweiz Med Wochenschr; 1996 Jan; 126(1-2):6-14. PubMed ID: 8571113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.
    Yasuda M; Gan L; Chen B; Kadirvel S; Yu C; Phillips JD; New MI; Liebow A; Fitzgerald K; Querbes W; Desnick RJ
    Proc Natl Acad Sci U S A; 2014 May; 111(21):7777-82. PubMed ID: 24821812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Acute hepatic porphyrias: pathophysiology and pathogenesis of acute attacks].
    Yasuda M
    Rinsho Shinkeigaku; 2024 Jan; 64(1):8-16. PubMed ID: 38092415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute hepatic porphyrias-A guide for hepatologists.
    Moghe A; McGuire BM; Levy C
    Hepatology; 2024 Apr; ():. PubMed ID: 38607698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurology of the acute hepatic porphyrias.
    Oliveira Santos M; Leal Rato M
    J Neurol Sci; 2021 Sep; 428():117605. PubMed ID: 34375916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute hepatic porphyrias: Identification of 46 hydroxymethylbilane synthase, 11 coproporphyrinogen oxidase, and 20 protoporphyrinogen oxidase novel mutations.
    Loskove Y; Yasuda M; Chen B; Nazarenko I; Cody N; Desnick RJ
    Mol Genet Metab; 2019 Nov; 128(3):352-357. PubMed ID: 30385147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurovisceral porphyrias: what a hematologist needs to know.
    Bonkovsky HL
    Hematology Am Soc Hematol Educ Program; 2005; ():24-30. PubMed ID: 16304355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical, Biochemical and Molecular Characteristics of the Main Types of Porphyria.
    Szlendak U; Bykowska K; Lipniacka A
    Adv Clin Exp Med; 2016; 25(2):361-8. PubMed ID: 27627571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drugs and acute porphyrias: reasons for a hazardous relationship.
    Roveri G; Nascimbeni F; Rocchi E; Ventura P
    Postgrad Med; 2014 Nov; 126(7):108-20. PubMed ID: 25387219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Porphyrias-what is verified?].
    Stölzel U; Kubisch I; Stauch T
    Internist (Berl); 2018 Dec; 59(12):1239-1248. PubMed ID: 30328490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute intermittent porphyria: pathophysiology and treatment.
    Khanderia U; Bhattacharya A
    Pharmacotherapy; 1984; 4(3):144-50. PubMed ID: 6377248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Hepatic Porphyria.
    Bissell DM; Wang B
    J Clin Transl Hepatol; 2015 Mar; 3(1):17-26. PubMed ID: 26357631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
    Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M;
    J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pain in acute hepatic porphyrias: Updates on pathophysiology and management.
    Kazamel M; Pischik E; Desnick RJ
    Front Neurol; 2022; 13():1004125. PubMed ID: 36479055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Best practice guidelines on first-line laboratory testing for porphyria.
    Woolf J; Marsden JT; Degg T; Whatley S; Reed P; Brazil N; Stewart MF; Badminton M
    Ann Clin Biochem; 2017 Mar; 54(2):188-198. PubMed ID: 27555665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brazilian registry of patients with porphyria: REBRAPPO study.
    Souza PVS; Afonso G; de Rezende Pinto WBV; de Lima Serrano P; de Mattos Lombardi Badia B; Farias IB; Dos Santos Jorge AC; Machado RIL; Pinto IFN; Barros GB; de Oliveira HB; Calil SR; Franz C; Oliveira ASB
    Orphanet J Rare Dis; 2023 Mar; 18(1):49. PubMed ID: 36890577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels.
    Agarwal S; Habtemarium B; Xu Y; Simon AR; Kim JB; Robbie GJ
    JIMD Rep; 2021 Jan; 57(1):85-93. PubMed ID: 33473344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.